A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease
Paola Papaldo(Cancer Institute (WIA)), F. Cognetti(Sapienza University of Rome), Paolo Carlini(National Cancer Institute), I Sacchi(Cancer Institute (WIA)), Marcella Mottolese, Alessandra Fabi(Agostino Gemelli University Polyclinic), Serena Di Cosimo(Fondazione IRCCS Istituto Nazionale dei Tumori), G. Ferretti(Istituti di Ricovero e Cura a Carattere Scientifico), Isabella Sperduti(San Gallicano Hospital), Maria Simona Pino(Massachusetts General Hospital), C. Nardoni(Cancer Institute (WIA)), Barbara Di Cocco(Tumori Foundation), Anna Maria Cianciulli
Cited by 82
Related Papers
The Chromosomal Instability Pathway in Colon Cancer
|Gastroenterology|2010|932
Bortezomib Sensitizes Pancreatic Cancer Cells to Endoplasmic Reticulum Stress-Mediated Apoptosis
|Cancer Research|2005|307
CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
|Journal of Clinical Oncology|2015|253